Veracyte Inc. Signals Durable Growth in Earnings Call

Veracyte Inc ((VCYT)) has held its Q4 earnings call. Read on for the main highlights of the call.

Veracyte Inc.’s latest earnings call struck a confident tone, as management highlighted strong top-line momentum, expanding margins, and robust cash generation. While they acknowledged near-term headwinds from one-time collections and heavier investment ahead of new product launches, the overall message was one of durable growth supported by a scalable platform and a deep evidence-based pipeline.

Strong Revenue Growth

Veracyte delivered Q4 revenue of about $140.6 million, up 19% from a year earlier, capping full-year 2025 sales of $517 million. That annual figure represents 16% growth and lands at the high end of the company’s preliminary range, signaling solid execution despite reimbursement and macro uncertainties.

Testing Revenue and Volume Expansion

Testing revenue rose 21% year over year in Q4 to $135.8 million, powered by roughly 48,000 total tests, up 16%. Afirma volumes climbed about 12% to 18,250 tests, while Decipher reached roughly 27,200 tests and notched its 15th straight quarter of more than 20% volume growth, underscoring broad adoption.

Improving ASP and Gross Margin

Average selling price for testing reached about $2,984 in Q4, up 4% year over year, or 1% on a normalized basis excluding prior-period collections. Non-GAAP gross margin improved sharply to 75.1%, with testing gross margin at 76.1%, helped by the lower-cost transcriptome platform and the benefit of one-time collections.

Industry-Leading Profitability and Cash Generation

Adjusted EBITDA hit $42.3 million in Q4, representing a 30.1% margin, while full-year adjusted EBITDA margin reached 27.6%, topping the company’s 25% target more than a year early. Veracyte posted GAAP net income of $41.1 million in the quarter and $66.4 million for the year, generated $52.6 million of operating cash, and ended Q4 with $412.9 million in cash and equivalents.

Platform Execution and Operational Efficiency

The company completed the migration of its Afirma test to the v2 transcriptome platform, which is more scalable and lower cost, and has already reduced the no-result rate by about two percentage points quarter over quarter. This transition, paired with restructuring of the Veracyte SAS unit, supports better throughput and a leaner cost structure going forward.

Decipher Clinical Momentum and Adoption

Decipher continued to be a key growth engine, with ordering physicians rising 18% year over year in Q4 and total prostate patients tested now exceeding 300,000. More than 100,000 prostate patients were tested in 2025 alone, and management estimates about 33% market penetration, supporting expectations for sustained double-digit growth after a 27% revenue increase in the quarter.

Evidence and Research Engine

Management underscored the depth of its data and publications, noting that Decipher prostate has more than 100 clinical utility and validity papers plus roughly 100 GRID research publications. Additional abstracts at major oncology meetings and ongoing Afirma GRID research are expected to further reinforce physician confidence and provide a platform for new signatures and future products.

Product Pipeline and 2026 Launches

Veracyte laid out a clear 2026 launch roadmap, anchored by TrueMRD for muscle invasive bladder cancer and a Prosigna lab-developed test on its new transcriptome workflow. TrueMRD is targeted for the first half of 2026 following a MolDX technical review, while the Prosigna launch is planned for the summer, positioning the company for multi-year expansion in oncology diagnostics.

Digital Pathology and Data Assets

The company has now integrated slide scanning into its standard production workflow, having digitized more than 210,000 slides from over 150,000 patients with outcomes data. This combined digital pathology and transcriptome dataset forms a powerful foundation for future AI models and biomarker discovery, potentially opening new revenue streams and clinical applications.

Guidance and Growth Targets for 2026

Looking ahead, Veracyte reiterated 2026 revenue guidance of $570 million to $582 million, implying 10% to 13% growth, with testing revenue expected to rise 14% to 16%, driven by about 20% growth in Decipher and mid- to high-single-digit growth in Afirma. The outlook excludes contributions from the 2026 launches and prior-period collections, incorporates a roughly $10 million headwind, and assumes an adjusted EBITDA margin near 25%, with seasonally softer profitability in the first quarter.

In sum, Veracyte’s call painted the picture of a diagnostics company balancing near-term investment and some reimbursement uncertainty against strong volume growth, rising margins, and a rich data-driven pipeline. For investors, the story hinges on sustained Decipher adoption, continued platform efficiencies, and the successful rollout of TrueMRD and Prosigna, which together could underpin the next leg of growth beyond 2026.